SABSW 0.05 SAB Biotherapeutics, Inc.
| Range: | 0.0487-0.05 | Vol Avg: | 0 | Last Div: | 0 | Changes: | 0.01 |
| Beta: | 0.7 | Cap: | 0.03B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Mon Oct 25 2021 | Empoloyees: | 57 | ||
| CUSIP: | 78397T111 | CIK: | 0001833214 | ISIN: | US78397T1117 | Country: | US |
| CEO: | Mr. Samuel J. Reich | Website: | https://www.sabbiotherapeutics.com | ||||
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow